John M. Burke, MD


Circulating Tumor DNA Measurement in Lymphoma One of the Big Stories From ASH

John M. Burke, MD, highlights progress in the field of hematology and oncology presented at the 64th American Society of Hematology Annual Meeting and Exposition.

Mehrdad Abedi, MD


Exploring the Use of Orca-T for Patients With Acute and Chronic GVHD

Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.

Bruno Lemos, PhD


World Cancer Day: Next Generation Sequencing at the Forefront of Precision Medicine

Next generation sequencing is at the forefront of where technology and oncology intersect to help optimize patient outcomes and expand the overall field of cancer care.

Milind Javle, MD


Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCC

Milind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.

Anjana Patel, BSc


Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot Study

Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.

Salman Fazal, MD


Comparing Older Sibling Donors to Younger Unrelated Donors for SCT

Salman Fazal, MD, discusses the use cases for older matched sibling donors vs younger unrelated donors in stem cell transplants for patients with cancer.

Charles Powell, MD, MBA


Anti-HER2 Treatments Can Cause Pulmonary Toxicities in HER2+ Breast Cancer

Charles Powell, MD, MBA, discusses the questions surrounding pulmonary toxicities when using anti-HER2 monoclonal antibodies such as trastuzumab deruxtecan for patients with HER2-positive metastatic breast cancer.

Cary Gross, MD


Link Between Medicaid and Rates of Biomarker Testing in NSCLC

Cary Gross, MD, discusses the findings from a retrospective study which revealed there to be an association between Medicaid insurance, rates of biomarker testing, and patient outcomes among patients with advanced non–small cell lung cancer.

Mary F. Mulcahy, MD


Implications of the EPOCH Trial in Clinical Practice

Mary F. Mulcahy discusses the potential implications of the EPOCH trial in clinical practice.

Ryan Sugarman, MD


Takeaways From CheckMate-649 in Gastric/GEJ/Esophageal Cancers

Ryan Sugarman, MD, discusses the key takeaways from the CheckMate-649 trial of patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma receiving nivolumab combined with chemotherapy compared with chemotherapy alone in the first-line.

Raajit Rampal, MD, PhD


Unmet Needs for Treating Myelofibrosis Beyond Symptoms

Raajit Rampal, MD, PhD, discusses unmet needs for therapies to treat patients with myelofibrosis.

Wendy Stock, MD


Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?

Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.

Riad Salem, MD, MBA


Case 4: Later Lines of Therapy for Patients With Recurrent HCC

Expert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.

David Barrington, MD


Future Directions for Treating Stage 1B, Grade 3 Endometrial Cancer

David Barrington, MD, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.

Ketan K. Badani, MD


Exploring Therapies in Combination With Cytoreductive Nephrectomy in RCC

Ketan K. Badani, MD, discusses whether cytoreductive nephrectomies are efficacious when combined with immunotherapeutic agents in patients with renal cell carcinoma.

Thomas Hutson, MD, PharmD


Managing Adverse Events with Superior Combination Therapies in RCC

Thomas Hutson, MD, PharmD, discusses management strategies when confronting adverse events using combination therapies in treating patients with renal cell carcinoma.

Nizar Bahlis, MD


Updated MAIA Trial Data Show Improved Survival for Multiple Myeloma

Nizar Bahlis, MD, discusses the findings from the randomized phase III MAIA trial, which evaluated the combination regimen of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in transplant-ineligible patients with multiple myeloma.

Allison Rosenzweig, PhD


World Pancreatic Cancer Awareness Day: Advances in Pancreatic Cancer Detection and Treatment

Lynn M. Matrisian, PhD, MBA, and Allison Rosenzweig, PhD, from Pancreatic Cancer Action Network, review advances in the pancreatic cancer setting for World Pancreatic Cancer Awareness Day.

Connie L. Batlevi, MD, PhD


Tazemetostat Shows Benefit in EZH2-Mutated Follicular Lymphoma

Connie L. Batlevi, MD, PhD, discusses the efficacy of tazemetostat in patients with follicular lymphoma and an EZH2 mutation.

Patrick Wagner, MD, FACS


Gut Microbiome Shows Potential as New Option for Patients With Colorectal Cancer

In an interview with Targeted Oncology, Patrick Wagner, MD, FACS, discussed the possibility of using the gut microbiome for patients with colorectal cancer, as well as his own research on the topic.

Jonathan L. Kaufman, MD


Where Does Inhibition of BCL-2 Family Proteins Fit into the Multiple Myeloma Treatment Landscape?

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Drs. Shaji Kumar and Jonathan Kaufman discuss how BCL-2 inhibitors fit into the different treatment options for multiple myeloma.

Matthew T. Campbell, MD, MS


Survival Outcomes for Metastatic RCC and Sarcomatoid Dedifferentiation

Matthew T. Campbell, MD, discusses survival outcomes for patients with both metastatic renal cell carcinoma and sarcomatoid dedifferentiation and how they each have evolved over the past few years.

Will Pizii


Clinical Activity Is Found With Triplet Combination and ADCs in HER2-Mutant MBC

Results from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.

Rachel Grisham, MD


PR-Driven Approaches to Treating Granulosa Cell Tumors

Even though most early stage adult patients with granulosa cell tumors experience an excellent outcome, up to 33% of patients will eventually develop a tumor relapse. Recurrence may be detected many years after the initial treatment, thus prolonged surveillance is necessary.

Ross F. Harrison, MD


PARP Inhibitor Costs Give Patients With Ovarian Cancer Financial Toxicity

Ross F. Harrison, MD, discusses the out-of-pocket costs for patients with ovarian cancer receiving PARP inhibitor treatment.

Nicholas Wrigley


Cabozantinib and Immunotherapy Combination Improves Efficacy in Advanced Renal Cell Cancer Subgroups

Cabozantinib improved outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among poor-risk patients in combination with nivolumab and ipilimumab.

Lisa B. Ercolano, MD


Sarcoma Awareness Month: Helping Patients with Osteosarcoma Requires Multidisciplinary Approach

For sarcoma awareness month, Lisa Ercolano, MD, discusses the need for a multidisciplinary approach to treating patients with osteosarcoma.

Robert J. Soiffer, MD


Soiffer Discusses Relapse After Transplant

Robert J. Soiffer, MD, discusses the role of transplantation and relapse after transplant for patients with cancer.

Expert in oncology
Allison Betof Warner, MD, PhD


Role of Tumor-Infiltrating Lymphocytes in Solid Tumors: Advancements in Therapeutic Strategy

In the first interview of this series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale of tumor-infiltrating lymphocytes and considers their potential use in the management of solid tumors.